immunotherapy

Abstracts
Building an Episode of Care to Reduce Time to Treatment
08/23/2024
When previously identifying causes of delay in cancer treatment, existing workflows often did not provide consistent timelines estimated for providers to diagnose and treat patients. To reduce time to treatment, researchers employed a pilot...
When previously identifying causes of delay in cancer treatment, existing workflows often did not provide consistent timelines estimated for providers to diagnose and treat patients. To reduce time to treatment, researchers employed a pilot...
When previously identifying...
08/23/2024
Cancer Care Business Exchange
Case Q&A
Cutaneous Squamous Cell Carcinoma of the Scalp: The Role of Surgery, Nonsurgical Intervention, and Immunotherapy
04/26/2024
This Case Q&A presents an 84-year-old male with advanced squamous cell carcinoma of the scalp.
This Case Q&A presents an 84-year-old male with advanced squamous cell carcinoma of the scalp.
This Case Q&A presents an...
04/26/2024
ePlasty
Case Report
Case Report and Literature Review of Giant Cutaneous Malignant Melanoma: What’s Keeping Patients Away?
09/23/2022
This case report presents one of the largest cases of giant cutaneous malignant melanoma to date and the first in the literature to show excellent response to adjuvant immunotherapy.
This case report presents one of the largest cases of giant cutaneous malignant melanoma to date and the first in the literature to show excellent response to adjuvant immunotherapy.
This case report presents one of...
09/23/2022
ePlasty
News
Optimal Real-World Immunochemotherapy Regimen for Patients With MCL
06/25/2020
A study presented at the European Hematology Association (EHA) Annual Meeting (June 11-21, 2020) shed light on real-world outcomes in patients with mantle cell lymphoma (MCL) who were treated with rituximab plus...
A study presented at the European Hematology Association (EHA) Annual Meeting (June 11-21, 2020) shed light on real-world outcomes in patients with mantle cell lymphoma (MCL) who were treated with rituximab plus...
A...
06/25/2020
Journal of Clinical Pathways
The Real-World Lifetime Economic Burden of Urothelial Carcinoma by Stage at Diagnosis
Research Reports
The Real-World Lifetime Economic Burden of Urothelial Carcinoma by Stage at Diagnosis
05/19/2020
Abstract: Urothelial carcinoma (UC) is generally diagnosed early and may incur significant lifetime costs. This study estimated, from the payer’s perspective, the lifetime costs among patients diagnosed with UC...
Abstract: Urothelial carcinoma (UC) is generally diagnosed early and may incur significant lifetime costs. This study estimated, from the payer’s perspective, the lifetime costs among patients diagnosed with UC...
...
05/19/2020
Journal of Clinical Pathways
From the Field
Evolving the Delivery of CAR T-Cell Therapies to the Outpatient Setting
10/15/2018
Abstract: The availability of adoptive cell therapies allows clinicians to genetically reprogram patients’ own immune cells to find and attack cancer cells throughout the body. Chimeric antigen receptor (CAR)...
Abstract: The availability of adoptive cell therapies allows clinicians to genetically reprogram patients’ own immune cells to find and attack cancer cells throughout the body. Chimeric antigen receptor (CAR)...
...
10/15/2018
Journal of Clinical Pathways
Research in Review
Novel Prostate Cancer Biomarkers May Improve Targeted Therapy
08/15/2017
JCP Editors
Recent research has uncovered a new cause of treatment resistance in prostate cancer, which may improve targeted therapy efforts. Mutations within the SPOP gene are the most frequently documented genetic changes in...
Recent research has uncovered a new cause of treatment resistance in prostate cancer, which may improve targeted therapy efforts. Mutations within the SPOP gene are the most frequently documented genetic changes in...
Recent...
08/15/2017
Journal of Clinical Pathways
Research in Review
Monotherapy Improves Outcomes in Metastatic Breast Cancer With BRCA Mutation
08/14/2017
JCP Editors
An immuno-agent improves progression-free survival (PFS) and lowers the risk of death for patients with human epidermal growth factor 2 (HER2)-negative metastatic breast cancer and a germline BRCA mutation, according...
An immuno-agent improves progression-free survival (PFS) and lowers the risk of death for patients with human epidermal growth factor 2 (HER2)-negative metastatic breast cancer and a germline BRCA mutation, according...
An...
08/14/2017
Journal of Clinical Pathways
Research in Review
Comparative Effectiveness Study Identifies Optimal Therapy for MCL
08/02/2017
JCP Editors
A recent study showed improved long-term survival outcomes and quality of life (QoL) for patients with mantle cell lymphoma (MCL) receiving tyrosine kinase inhibitor (TKI) therapy compared with those receiving...
A recent study showed improved long-term survival outcomes and quality of life (QoL) for patients with mantle cell lymphoma (MCL) receiving tyrosine kinase inhibitor (TKI) therapy compared with those receiving...
A...
08/02/2017
Journal of Clinical Pathways
Research in Review
Optimal Therapy for Type of B-Cell Malignancy
08/02/2017
JCP Editors
A recent study showed improved long-term survival outcomes and quality of life (QoL) for patients with mantle cell lymphoma (MCL) receiving tyrosine kinase inhibitor (TKI) therapy compared with those receiving...
A recent study showed improved long-term survival outcomes and quality of life (QoL) for patients with mantle cell lymphoma (MCL) receiving tyrosine kinase inhibitor (TKI) therapy compared with those receiving...
A...
08/02/2017
Journal of Clinical Pathways

Upcoming Events

February 2 ⁠–⁠ February 5
Western AF Symposium
February 27 ⁠–⁠ March 1
DCLF
March 17 ⁠–⁠ March 19
NP Institute
March 27 ⁠–⁠ March 30
TCIV
March 31 ⁠–⁠ April 2
Rx summit logo
April 21 ⁠–⁠ April 24
SAWC Spring
April 30 ⁠–⁠ May 4
Symposium on Advanced Wound Care
April 30 ⁠–⁠ May 5
WoundCon
May 1 ⁠–⁠ May 3
Senior Living Executive Conference
May 19 ⁠–⁠ May 21
See Full Calendar

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2024 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use